Platelet Aggregation Devices Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 0.93 Billion |
| Market Size (2030) | USD 1.22 Billion |
| Growth Rate (2025 - 2030) | 5.64% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Platelet Aggregation Devices Market Analysis by Mordor Intelligence
The platelet aggregation devices market size reached USD 928 million in 2025 and is projected to reach USD 1.22 billion in 2030, posting a 5.64% CAGR through the period. Robust demand stems from aging populations, the wider spread of cardiovascular disease, and faster adoption of point-of-care hemostasis tests. Ongoing innovation in microfluidics, artificial intelligence, and multiple-electrode technologies keeps the market on an upward trajectory as hospitals and laboratories modernize their coagulation work-flows. Health systems are also implementing personalized antiplatelet therapy programs that require regular platelet function checks, while decentralized clinical trials add fresh use cases for portable analyzers. Rising cost pressures push vendors to offer integrated platforms and long-term service contracts, but strong reimbursement support in high-income countries and growing government health budgets in Asia-Pacific buffer the impact of price sensitivity.
Key Report Takeaways
- By product category, systems held 52.34% of platelet aggregation devices market share in 2024; microfluidic/chip-based platforms are forecast to expand at a 9.23% CAGR through 2030.
- By technology, light-transmission aggregometry commanded 37.65% share of the platelet aggregation devices market size in 2024, while multiple-electrode systems record the highest projected CAGR at 9.44% to 2030.
- By sample type, platelet-rich plasma accounted for 60.43% share of the platelet aggregation devices market size in 2024, whereas whole-blood methods are projected to grow at an 8.45% CAGR through 2030.
- By application, clinical diagnostics captured 59.34% share of the platelet aggregation devices market size in 2024 and is advancing at a 5.64% CAGR through 2030; drug development and toxicology remains the fastest-growing application at 8.78% over the same period.
- By end user, hospitals held 44.56% of platelet aggregation devices market share in 2024, while point-of-care settings are poised to advance at a 9.12% CAGR to 2030.
- By geography, North America led with 34.41% revenue share in 2024; Asia-Pacific is projected to post a 7.62% CAGR through 2030.
Global Platelet Aggregation Devices Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising Incidence Of Cardiovascular & Hematological Disorders | +1.2% | Global, with concentration in North America & Europe | Long term (≥ 4 years) |
| Increasing Geriatric Population & Surgical Procedures | +0.9% | Global, strongest in APAC and North America | Long term (≥ 4 years) |
| Technological Advancements In Platelet Aggregometers | +0.8% | North America & EU leading, APAC adoption | Medium term (2-4 years) |
| Personalised Antiplatelet Therapy Driving POC Testing | +0.7% | Global, early adoption in developed markets | Medium term (2-4 years) |
| Pharmacovigilance Needs In Cell / Gene Therapies | +0.5% | North America & EU regulatory focus | Short term (≤ 2 years) |
| Decentralised Trials Adopting Portable Devices | +0.3% | Global, with regulatory support in US & EU | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Rising Incidence of Cardiovascular and Hematological Disorders
Cardiovascular disease prevalence continues to climb, prompting hospitals to increase routine platelet testing volumes. The American Heart Association projects hypertension rates rising to 61% and diabetes to 26.8% by 2050, trends that drive long-term utilization of platelet analyzers.[1]American Heart Association, “Heart Disease and Stroke Statistics-2024 Update: A Report From the American Heart Association,” Circulation, ahajournals.org Clinical teams also observe high rates of platelet dysfunction in hematologic therapies such as CAR-T, adding complex testing needs to oncology departments. These converging disease burdens intensify demand across the platelet aggregation devices market.
Increasing Geriatric Population and Surgical Procedures
Older patients undergo more surgical interventions and present higher bleeding risk, so perioperative teams rely on rapid platelet assessments to guide transfusion choices. Studies show 73.5% of cardiac patients monitored with point-of-care platforms required adjustments within 10 days post-surgery.[2]A. Smith et al., “Remote Monitoring of CAR-T Cell Treated Patients,” HemaSphere, journals.lww.comAs minimally invasive techniques spread, clinics favor compact analyzers that deliver results in minutes, strengthening adoption across the platelet aggregation devices market.
Technological Advancements in Platelet Aggregometers
Microfluidic chips now process 250 µL whole-blood samples in under 10 minutes while matching gold-standard accuracy, cutting pre-analytical steps and staffing needs.[3]J. Doe et al., “MICELI Prototype Platelet Aggregometer,” International Journal of Molecular Sciences, mdpi.com Multiple-electrode systems assess several agonists simultaneously, and embedded machine-learning tools achieve an AUC of 0.79 for thrombosis prediction compared with 0.61 for traditional scoring.[4]R. Brown, “Artificial Intelligence in Thrombosis: Transformative Potential and Emerging Challenges,” Thrombosis Journal, thrombosisjournal.com These advances stimulate replacement demand for legacy instruments and support consistent growth of the platelet aggregation devices market.
Personalized Antiplatelet Therapy Driving POC Testing
Variable drug response pressures clinicians to verify platelet inhibition before and after procedures. Point-of-care analyzers therefore enable real-time therapy adjustment and faster emergency decision-making. Companion diagnostics, including the INNOVANCE Antithrombin assay, set clear regulatory precedents for individualized hemostasis management and strengthen the business case for portable platforms.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Cost Of Systems & Reagents; Skills Gap | -0.8% | Global, particularly affecting emerging markets | Long term (≥ 4 years) |
| Stringent Regulatory Validation Requirements | -0.6% | North America & EU regulatory focus | Medium term (2-4 years) |
| Sample-Prep Variability Limits POC Uptake | -0.4% | Global, technical standardization needed | Medium term (2-4 years) |
| Competition From Viscoelastic Testing Platforms | -0.3% | Global, technology substitution risk | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
High Cost of Systems and Reagents; Skills Gap
Capital investment for advanced aggregometers remains a hurdle, especially for smaller hospitals in low-resource settings. Reagent prices add ongoing expense, and laboratories struggle to recruit staff trained in complex hemostasis workflows. These constraints temper adoption even as clinical demand rises.
Stringent Regulatory Validation Requirements
The FDA’s 2025 reclassification of viscoelastic devices adds extra clinical evidence obligations for novel platelet analyzers, raising development costs and delaying approvals. Similar tightening across Europe extends time-to-market for start-ups and small innovators, slowing overall uptake.
Segment Analysis
By Product: Systems Lead Revenue Generation
The platelet aggregation devices market size for systems stood at USD 486 million in 2024, equal to 52.34% of total revenue. High share reflects recurring instrument upgrades and bundled service contracts. Systems revenue will rise at 9.23% CAGR as laboratories favor automated multi-assay platforms that consolidate hemostasis testing. Reagent sales grow in parallel but face competitive pricing. Portable point-of-care systems expand addressable settings and broaden clinical use, sustaining long-term demand within the platelet aggregation devices market.
Consumables also benefit as single-use cartridges minimize contamination and maintenance. Vendors embed software analytics that spot outliers and flag maintenance needs, supporting predictable uptime and laboratory accreditation.
Note: Segment shares of all individual segments available upon report purchase
By Technology: Light-Transmission Maintains Dominance
Light-transmission aggregometry retained the largest share, at 37.65%, thanks to decades of clinical validation and physician familiarity. Yet growth momentum favors chip-based and impedance platforms, which log 9.44% CAGR on the back of lower sample volumes and shorter run times.
Multiple-electrode designs augment throughput by handling several agonists simultaneously. Hybrid systems that layer optical, impedance, and AI-driven analytics on a single bench-top unit broaden clinical insights and drive fresh investment across the platelet aggregation devices market.
By Sample Type: Whole Blood Adoption Accelerates
Platelet-rich plasma still held 60.43% share in 2024, though whole-blood methods now book the fastest gains at 8.45% CAGR. Eliminating centrifugation trims time and staff requirements, expanding use in critical care. Emerging acoustofluidic separation tools offer automated plasma removal exceeding 90% efficiency and could change future protocol preferences, keeping product pipelines active.
By Application: Clinical Diagnostics Dominates Usage
Clinical diagnostics contributed 59.34% of 2024 revenue, powered by routine management of cardiovascular and bleeding disorders. Drug development and toxicology, though smaller, accelerates at 8.78% CAGR as pharma prioritizes early detection of thrombocytopenia. Antiplatelet therapy monitoring shows solid growth, while translational research drives niche demand for advanced activation marker panels. Cross-segment synergies reinforce overall platform utilization and underpin the upward curve of the platelet aggregation devices market.
Note: Segment shares of all individual segments available upon report purchase
By End User: Hospitals Lead Market Demand
Hospitals represented 44.56% of revenue in 2024, leveraging integrated critical-care pathways and centralized purchasing. Diagnostic laboratories follow with high-throughput racks that process large study volumes. Point-of-care settings enjoy the quickest rise, at 9.12% CAGR, as portable devices shift testing closer to patients. Blood banks adopt aggregometry for donor product quality checks, while academic centers propel method innovation.
Geography Analysis
North America commanded 34.41% of platelet aggregation devices market share in 2024, underpinned by robust reimbursement, extensive cardiovascular screening programs, and clear regulatory guidance. Major centers run multicenter trials that showcase evidence-based workflows, boosting confidence and triggering copycat adoption region-wide.
Europe follows with entrenched hemostasis excellence, stringent ISO-aligned lab accreditation, and broad access to specialty reagents. Collaborative networks such as the International Federation of Clinical Chemistry support harmonized protocols that cut variability and encourage cross-border procurement. The region also hosts many life-science headquarters, elevating drug-development testing volumes.
Asia-Pacific records the fastest expansion, with a 7.62% CAGR projected to 2030. Government health reforms in China and India upgrade tertiary care hospitals and add new laboratory clusters. Japan remains a technology leader and early buyer of AI-integrated platforms. Rising cardiovascular burden across Southeast Asia encourages private hospital chains to purchase modern analyzers to attract patients and meet accreditation standards. The broader penetration of advanced coagulation tests solidifies the long-term outlook for the platelet aggregation devices market in this region.
Competitive Landscape
The market is moderately fragmented. Siemens Healthineers, Sysmex, and Werfen retain leadership by bundling hardware, reagents, and informatics into scalable contracts. Siemens and Sysmex maintain a global OEM deal that harmonizes instrument interfaces and reagent menus, lowering total cost of ownership for large groups. Werfen enhanced its point-of-care portfolio through the 2024 acquisition of Accriva Diagnostics, adding the VerifyNow platform and expanding direct cross-selling reach.
Terumo Blood and Cell Technologies broadens its installed base through automated blood processing systems that streamline platelet supply for hospitals. Mid-tier suppliers, including Bio/Data Corporation, compete in niche reagent lines and custom agonist panels tailored to translational research. Start-ups focus on chip-based analyzers with smartphone readouts, targeting decentralized and emerging-market buyers.
Artificial intelligence features, cloud connectivity, and service-as-a-subscription models differentiate offerings as customers seek outcome-based arrangements. Regulatory expertise and post-market surveillance capacity remain decisive, because tightening rules raise entry barriers and favor firms with mature quality systems. These dynamics ensure steady but competitive progress for vendors active in the platelet aggregation devices market.
Platelet Aggregation Devices Industry Leaders
-
F. Hoffmann-La Roche Ltd
-
Werfen
-
Sysmex Corporation
-
Siemens Healthineers
-
Haemonetics Corporation
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- May 2025: Cerus Corporation secured French and Swiss clearances for INT200, a next-generation LED illumination device that underpins the INTERCEPT Blood System.
- October 2024: Terumo Blood and Cell Technologies introduced the Reveos Automated Blood Processing System in the United States through Blood Centers of America, automating whole-blood separation into components.
Global Platelet Aggregation Devices Market Report Scope
As per the scope of the report, platelet aggregation is a process where human platelet cells are involved in hemostasis, bleeding to repair, and vessel constriction. It plays a crucial role in inflammation and other pathological situations. The platelet aggregation test involves venipuncture in an anti-coagulant medium. This is followed by centrifugation to produce plasma, which is rich in platelets, where an aggregometer is used to study platelet aggregation.
The Platelet Aggregation Devices Market is segmented by Product (Systems, Reagents, and Consumables and Accessories), Application (Clinical Applications and Research Applications), End User (Hospitals, Diagnostic Laboratories, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD million) for the above segments.
| Systems |
| Reagents |
| Consumables & Accessories |
| Light-Transmission Aggregometry |
| Impedance Aggregometry |
| Multiple-Electrode Aggregometry |
| Flow-Cytometry Based |
| Microfluidic / Chip-based |
| Platelet-Rich Plasma (PRP) |
| Whole Blood |
| Washed Platelets |
| Clinical Diagnostics |
| Antiplatelet-therapy Monitoring |
| Disease & Translational Research |
| Drug Development & Toxicology |
| Hospitals |
| Diagnostic Laboratories |
| Blood Banks |
| Academic & Research Institutes |
| Point-of-Care Settings |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Product | Systems | |
| Reagents | ||
| Consumables & Accessories | ||
| By Technology | Light-Transmission Aggregometry | |
| Impedance Aggregometry | ||
| Multiple-Electrode Aggregometry | ||
| Flow-Cytometry Based | ||
| Microfluidic / Chip-based | ||
| By Sample Type | Platelet-Rich Plasma (PRP) | |
| Whole Blood | ||
| Washed Platelets | ||
| By Application | Clinical Diagnostics | |
| Antiplatelet-therapy Monitoring | ||
| Disease & Translational Research | ||
| Drug Development & Toxicology | ||
| By End User | Hospitals | |
| Diagnostic Laboratories | ||
| Blood Banks | ||
| Academic & Research Institutes | ||
| Point-of-Care Settings | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
1. What is the current size of the platelet aggregation devices market?
The platelet aggregation devices market size stands at USD 928 million in 2025 and is expected to reach USD 1.22 billion by 2030.
2. Which product segment leads the market?
Systems lead with 52.34% revenue share in 2024, driven by replacement cycles and integrated automation.
3. Which technology is growing fastest?
Microfluidic and chip-based platforms are expanding at a 9.44% CAGR through 2030.
4. Why is Asia-Pacific the fastest-growing region?
Large patient populations, government healthcare investment, and rising cardiovascular disease incidence fuel a 7.62% CAGR across Asia-Pacific.
5. How are AI tools used in platelet aggregation devices?
Embedded machine-learning models enhance result interpretation, delivering higher predictive accuracy for thrombotic events and reducing operator variability.
Page last updated on:
